Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

The FDA gave a green light for the biotech to begin phase 1 testing of its coronavirus vaccine candidate.

Why Vaxart Stock Is Crushing It Today

Shares of Vaxart Inc. VXRT, +10.87% jumped 15.6% in premarket trading on Monday after the company said it had received the go-ahead from the Food and Drug Administration to begin testing its experimental oral COVID-19 vaccine in a Phase 1 clinical trial.

Vaxart's stock rallies 15% after it gets clearance to begin human trials of COVID-19 vaccine candidate

Recruitment for Phase 1 clinical study expected to start this month

Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

Altimmune

These biotechs are developing coronavirus vaccines with a twist.

Better Coronavirus Stock: Altimmune or Vaxart?

San Francisco, California--(Newsfile Corp. - September 11, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm, Securities Fraud Class Action Filed and Application Deadline Approaching

San Francisco, California--(Newsfile Corp. - September 10, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm Now, Securities Fraud Class Action Filed and Application Deadline Approaching

CRISPR Therapeutics

From a painless vaccine to a method of fixing faulty genes, betting on these technologies may bring big rewards.

2 Game-Changing Biotech Stocks That May Make You Rich

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Vaxart, Inc.

Investor Alert: Kaplan Fox Investigates Vaxart For Potential Securities Fraud

San Francisco, California--(Newsfile Corp. - September 9, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses to Contact the Firm Now, Securities Fraud Class Action Filed and Important Deadline is Approaching

OPKO Health

QuidelOrtho Corp

Competition from heavy hitters spooked investors.

Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August

Amid the carnage in the technology sector over the last few sessions, the COVID-19 crisis has taken a backseat to a much-needed correction in the markets.

PreMarket Prep Stock Of The Day: Vaxart

Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vaxart, Inc. (NASDAQ: VXRT) between June 25, 2020 to July 25, 2020, inclusive (the “Class Period”), of the important October 23, 2020 lead plaintiff deadline in the case.

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT

AstraZeneca

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Pfizer

How to Invest in Coronavirus Vaccine Stocks

Dynavax Technologies

Sorrento Therapeutics Inc

CureVac B.V

Late to the rally in coronavirus vaccine stocks? Consider these four rising biotechs.

Got $3,000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a Bargain

San Francisco, California--(Newsfile Corp. - September 4, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action, Encourages Investors with Significant Losses to Contact its Attorneys

New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Vaxart, Inc.

Rosen, A Leading Law Firm, Announces Filing of Securities Class Action Lawsuit Against Vaxart, Inc. - VXRT

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th  - Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th  - SVB Leerink: CybeRx Series: Vaccine Forum - September 23rd & – 24th

Vaxart, Inc. to Participate in September Virtual Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #classaction--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vaxart, Inc. (VXRT)

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vaxart, Inc. (VXRT)

Vaxart: Too Early To Dismiss This COVID-19 Vaccine Opportunity

San Francisco, California--(Newsfile Corp. - September 1, 2020) -  Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Filed Securities Fraud Class Action, Encourages Investors with Significant Losses to Contact its Attorneys

New York, New York--(Newsfile Corp. - September 1, 2020) -  Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Vaxart, Inc.

VXRT Investor Update: Bronstein, Gewirtz & Grossman, LLC Notifies Vaxart, Inc. Investors of Class Action and Lead Plaintiff Deadline: October 23, 2020

Are these two COVID-19 vaccine stocks still worth buying?

These 2 Shocking Stocks Have Outperformed the S&P in 2020 -- by a Lot

BioNTech SE

GlaxoSmithKline

Heat Biologics

Sanofi

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

San Francisco, California--(Newsfile Corp. - August 28, 2020) - Hagens Berman announces that it has filed a class action lawsuit against Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors: Securities Fraud Class Action Filed, Investors with Losses Encouraged to Contact its Attorneys Now

News for Vaxart Stock (VXRT)